Substance Use Disorder Treatment Services

Substance use disorder (SUD) treatment encompasses a structured continuum of clinical, behavioral, and pharmacological interventions designed to address problematic use of alcohol, opioids, stimulants, cannabis, and other psychoactive substances. Federal law classifies SUD as a chronic medical condition, and treatment services are subject to oversight by agencies including the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA). This page covers the definition and regulatory scope of SUD treatment, how care is structured and delivered, common clinical scenarios, and the boundaries that determine which level of care applies. Understanding this framework is relevant to anyone navigating mental health services in the US or behavioral health integration in medical settings.

Definition and scope

Substance use disorder is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association, as a pathological pattern of behavior related to substance use — categorized by severity as mild (2–3 criteria met), moderate (4–5 criteria), or severe (6 or more criteria out of 11 diagnostic criteria). This classification directly governs treatment authorization and insurance billing under the Mental Health Parity and Addiction Equity Act of 2008 (42 U.S.C. § 18031), which requires that SUD benefits not be more restrictive than medical/surgical benefits in health plans offering mental health coverage.

SAMHSA, operating under the U.S. Department of Health and Human Services, administers the primary federal grant program for SUD treatment through the Substance Abuse Prevention and Treatment Block Grant (SABG, 45 CFR Part 96). State behavioral health agencies distribute these funds. Licensed treatment facilities must also comply with federal confidentiality regulations under 42 CFR Part 2, which governs the privacy of substance use disorder patient records — a standard distinct from and in addition to HIPAA protections covered in health information privacy and HIPAA.

How it works

SUD treatment is organized along a continuum defined by the American Society of Addiction Medicine (ASAM) Patient Placement Criteria, now in its third edition (The ASAM Criteria). The ASAM framework uses six assessment dimensions — including intoxication/withdrawal potential, biomedical conditions, emotional/behavioral conditions, readiness to change, relapse potential, and recovery environment — to match patients to one of five broad levels of care.

The five ASAM levels are:

1. Level 0.5 — Early Intervention: Assessment and education for individuals at risk, not yet diagnosed with SUD.
2. Level 1 — Outpatient Services: Fewer than 9 hours of service per week; typically individual or group counseling.
3. Level 2 — Intensive Outpatient/Partial Hospitalization: 9–20 hours per week (intensive outpatient, Level 2.1) or 20 or more hours per week (partial hospitalization, Level 2.5).
4. Level 3 — Residential/Inpatient Services: 24-hour structured living environment; subdivided into clinically managed low-intensity (3.1) through medically monitored high-intensity (3.7) residential.
5. Level 4 — Medically Managed Intensive Inpatient: Acute care hospital setting with 24-hour physician-managed services, reserved for severe withdrawal or co-occurring medical instability.

Pharmacological treatment runs parallel to the ASAM levels. For opioid use disorder, the FDA has approved three medications: methadone (dispensed only through SAMHSA-certified Opioid Treatment Programs under 42 CFR Part 8), buprenorphine (prescribable in office-based settings following DEA registration), and naltrexone (available in oral and extended-release injectable formulations). For alcohol use disorder, FDA-approved medications include naltrexone, acamprosate, and disulfiram.

Common scenarios

Opioid use disorder with acute withdrawal risk: An individual presenting with physiological dependence on opioids and a COWS (Clinical Opiate Withdrawal Scale) score of 13 or higher typically warrants medically supervised withdrawal management at ASAM Level 3.7 or Level 4, followed by transition to medication-assisted treatment (MAT) and outpatient counseling.

Alcohol use disorder with co-occurring depression: Moderate-to-severe alcohol use disorder paired with a co-occurring psychiatric condition is frequently managed at ASAM Level 2.5 (partial hospitalization) where dual-diagnosis programming is available. SAMHSA's 2022 National Survey on Drug Use and Health (NSDUH) reported that approximately 9.2 million adults in the U.S. had co-occurring mental illness and a substance use disorder (SAMHSA NSDUH 2022).

Stimulant use disorder (methamphetamine or cocaine): No FDA-approved pharmacotherapy exists as of the DSM-5 era; treatment relies primarily on contingency management and cognitive-behavioral therapy delivered at ASAM Level 1 or Level 2.1. The National Institute on Drug Abuse (NIDA) identifies the Matrix Model as an evidence-based 16-week intensive outpatient approach specifically validated for stimulant disorders.

Adolescent SUD: Pediatric cases are governed by separate ASAM adolescent criteria. Treatment settings prioritize family involvement and educational continuity, often within pediatric medical services frameworks or school-based referral channels described under school and campus health services.

Decision boundaries

The boundary between SUD treatment levels hinges on three primary clinical variables: medical stability, psychiatric acuity, and social/environmental support.

Outpatient vs. residential: ASAM Criteria indicate residential placement when an individual's recovery environment is assessed as high-risk (e.g., active substance use in the home, homelessness) or when prior outpatient attempts have failed. Medical necessity standards — required by insurers under the Mental Health Parity and Addiction Equity Act — must be applied using ASAM Criteria or a clinically equivalent validated tool; arbitrary day limits or fail-first requirements are prohibited under parity law.

Medication-assisted treatment vs. abstinence-based programs: MAT is classified by SAMHSA and NIDA as the evidence-based standard for opioid use disorder, associated with reduced overdose mortality. Programs that prohibit FDA-approved medications as a condition of participation may not meet federal standards for Medicaid-funded treatment under 42 CFR Part 438.

Detoxification as a standalone service: Withdrawal management (detoxification) alone is not considered treatment for SUD under SAMHSA definitions. Detox addresses physiological stabilization; it does not constitute a complete episode of care. Linkage to ongoing treatment at an appropriate ASAM level is required to meet federal block grant program standards.

SUD treatment services intersect with chronic disease management services and coordinated and integrated care models, particularly for individuals with multiple chronic conditions requiring cross-system care coordination.

References

• Substance Abuse and Mental Health Services Administration (SAMHSA) — Federal agency overseeing SUD treatment programs, SABG grants, and OTP certification.
• SAMHSA 2022 National Survey on Drug Use and Health (NSDUH) — Annual national prevalence and co-occurrence data.
• 42 CFR Part 8 — Medication Assisted Treatment for Opioid Use Disorders (eCFR) — Federal regulation governing methadone OTP certification.
• 42 CFR Part 2 — Confidentiality of Substance Use Disorder Patient Records (eCFR) — Federal privacy standards specific to SUD records.
• National Institute on Drug Abuse (NIDA) — NIH institute publishing evidence-based treatment research, including the Matrix Model and MAT outcome data.
• American Society of Addiction Medicine (ASAM) — The ASAM Criteria — Standard patient placement framework for SUD treatment levels.
• U.S. Food and Drug Administration (FDA) — Medications to Treat Opioid Use Disorder — FDA-approved pharmacotherapy information for opioid and alcohol use disorders.
• Mental Health Parity and Addiction Equity Act (MHPAEA) — U.S. Department of Labor — Federal parity law governing SUD insurance benefit requirements.